TVGN · NASDAQ · Biotechnology

Tevogen Bio (TVGN)

Develops ExacTcell-based T-cell therapy candidates for COVID-19, cancer and Long COVID.

$6.92
Pre-market−0.25 (−3.49%)
At close$7.17(0.00%)

Something off on this page? Send us feedback.

Next report
Nov 13, 2026
estimated · in 71 days
EPS estimate
−$2.56
Revenue estimate
Fiscal quarter
Q3 FY26

EPSReportedEstimate

May '25Aug '25Nov '25Mar '26May '26Aug '26Aug '26Nov '26
Reported−$3.21−$0.03−$0.03−$1.20−$1.61−$1.52−$1.52Pending
Estimate−$0.05−$0.05−$0.06−$1.50−$2.64−$2.53−$2.53−$2.56
Surprise−6,494.4%+40.0%+50.7%+20.0%+39.0%+39.9%+39.9%

RevenueReportedEstimate

May '25Aug '25Nov '25Mar '26May '26Aug '26Aug '26Nov '26
ReportedPending
Estimate
Surprise

History

DateEstimateReportedSurprise
Nov 2026−$2.56
Aug 2026−$2.53−$1.52+39.9%
Aug 2026−$2.53−$1.52+39.9%
May 2026−$2.64−$1.61+39.0%
Mar 2026−$1.50−$1.20+20.0%

The latest year is open to everyone — the 19 quarters behind it read with an account.

Sign in
Nov 2025
Aug 2025
May 2025
Apr 2025
Nov 2024
Aug 2024
May 2024
Dec 2023
Sep 2023
Jun 2023
Mar 2023
Dec 2022
Sep 2022
Jun 2022
Mar 2022
Dec 2021
Sep 2021
Jun 2021
Jan 1970−$0.03
Report dateEPS estEPSSurpriseRevenue estRevenueSurpriseReaction
Nov 13, 2026−$2.56
Aug 14, 2026−$2.53−$1.52+39.9%−4.2%
Aug 13, 2026−$2.53−$1.52+39.9%+1.6%
May 15, 2026−$2.64−$1.61+39.0%+11.7%
Mar 31, 2026−$1.50−$1.20+20.0%−0.9%

The latest year is open to everyone — the 19 quarters behind it read with an account.

Sign in
Nov 14, 2025
Aug 19, 2025
May 14, 2025
Apr 2, 2025
Nov 19, 2024
Aug 14, 2024
May 27, 2024
Dec 31, 2023
Sep 30, 2023
Jun 30, 2023
Mar 31, 2023
Dec 31, 2022
Sep 30, 2022
Jun 30, 2022
Mar 31, 2022
Dec 31, 2021
Sep 30, 2021
Jun 30, 2021
Jan 1, 1970−$0.03